Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Deuremidevir Hydrobromide in Healthy Volunteers
NCT06328400Phase 1Completed
- Sponsor
- Vigonvita Life Sciences
- Start
- Mar 2024
- Primary completion
- May 2024
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of deuremidevir in respiratory syncytial virus infection (RSV) (3 arms), sponsored by Vigonvita Life Sciences. Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Mar 2024; status: completed.
02
Drugs
deuremidevir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06328400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06328400.